SRNE needs to address these issues:
1. why no clinical updates on product status? Moderna just updated its phase 1 clinical data, INVESTORS need to see how things are going, not just a "oh well, guess we'll just have to see what the FDA says" 5 or 6 months later.
2. how about an anecdotal update (at least) from Brazil? Covi-something is being used in Brazilian hospitals since mid-October, is it helping patients recover faster? Seem to be effective? Anything?
3. Covi-Track: Has it been shut down? About 8 weeks ago it was "with the FDA".... for pete's sake, if it is an accurate testing modality, why isn't it being used or brought to market? We were told "95 to 97% effective", what continues to be the delay? Make a statement on it Ji! The 8 minute game changer has been kept in its box long enough, either get it approved or announce that the company has switched gears to the Covi Trace/Mobile/etc. spit test instead.
4. Company put out in September that they were hiring or looking for a VP Investors Relations -- where is this at? During these times it is EXTREMELY important for news developments to be communicated by a qualified Investors Relations individual..... again Ji, where does this stand?
Losing patience with this.....